Longeveron Reports Positive Phase 2a Laromestrocel Data
MIAMI, July 13, 2026 Longeveron announced new analyses from its Phase 2a CLEAR MIND clinical trial demonstrating that its...
Longeveron
Advertisement
Longeveron Reports New Phase 2a Laromestrocel Alzheimer’s Data
Miami, Florida | June 18, 2026 Longeveron Inc. announced that an additional clinical data analysis from its Phase 2a...
Longeveron Reports Constructive FDA Meeting Ahead of ELPIS II HLHS Data Readout
MIAMI, Florida, United States – May 10, 2026 Longeveron announced details from a constructive Type C meeting with the...
Advertisement
